TherapeuticsMD, Inc. 8-K


Exhibit 99.1






TherapeuticsMD Announces Fourth Quarter and Full-Year 2018 Financial Results


-Successful Launch of IMVEXXY®, Strong Positive

Trends Continue for Prescriptions and Patient Refills-


-BIJUVA™ Commercial Launch on Track for the Second Quarter of 2019-


-ANNOVERA™ Commercial Launch planned as Early as the Third Quarter of 2019-


-Conference Call Scheduled for 4:30 p.m. ET Today-


BOCA RATON, Fla. February 21, 2019 – TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced its commercial and corporate update for the fourth quarter and full-year ended December 31, 2018.


“In 2018, we completed our most successful year to date and transformed into a leading women’s healthcare company,” said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD. “As we begin 2019, we are focused on executing the next phases of our commercialization strategy. IMVEXXY continues to deliver strong growth in prescriptions and in patient refill activity. Its success has laid the foundation for the upcoming launches of BIJUVA in the second quarter of this year and ANNOVERA as early as the third quarter of this year. We are enthusiastic about expanding our BIO-IGNITESM program with our compounding pharmacy partners that represent a large and important channel for physicians and patients in hormone therapy.”


IMVEXXY Launch Continues to Highlight Successful Launch Execution

The company commenced the U.S. commercial launch of IMVEXXY (estradiol vaginal inserts) 10-mcg dose in August 2018 and the 4-mcg dose in September 2018 with the support of 150 sales representatives. IMVEXXY is currently available in major U.S. pharmacy chains and through BIO-IGNITE compounding pharmacy partners. 

oApproximately 47,500 prescriptions of IMVEXXY were dispensed to approximately 22,200 patients during the fourth quarter of 2018. The 3-fold increase in prescription volume for the fourth quarter of 2018 as compared to our launch during the third quarter of 2018.
 oFrom launch through December 31, 2018, approximately 62,400 prescriptions were dispensed to approximately 25,500 patients and approximately 7,300 prescribers had a filled prescription for the product.
 oStrong refill rates suggest women are having a positive experience with IMVEXXY. Patients who began treatment in August 2018 have obtained an average of 4.9 refills through January 2019, out of a possible 6 refills.
 oThrough December 31, 2018, the company achieved unrestricted coverage with six of the top ten commercial payers, with three of them adjudicating on January 1, 2019. This includes two commercial payers that were added in the fourth quarter of 2018, which was a large contributor to the 4-fold increase in net revenue growth for IMVEXXY for the fourth quarter of 2018 as compared to our launch during the third quarter of 2018.




  o After year end, the company came to agreement for commercial coverage of IMVEXXY with United Healthcare, the third largest commercial payer in the U.S, to begin adjudication on March 1, 2019. Additionally, the company secured coverage from United Healthcare and Kaiser (limited to only the maintenance pack) for their Medicare Part D plans.
  o IMVEXXY prescription growth continues into 2019 as highlighted by a record month in January 2019.
  o IMVEXXY average weekly prescription volume for the first two weeks of February 2019 increased to approximately 5,800 as compared to average weekly volume of approximately 5,300 in January 2019.


Key Expected Events in 2019

1Q 2019 - Speaker medical education programs throughout the United States highlighting the clinical and physical attributes of IMVEXXY

1Q 2019 through 3Q 2019 – Expand IMVEXXY Part D coverage

1Q 2019 – Expand sales force by 25% to 200 sales representatives to increase reach of IMVEXXY and launch BIJUVA

2H 2019 - Begin direct-to-consumer marketing for IMVEXXY

2Q 2019 – U.S. commercial launch of BIJUVA (estradiol and progesterone) capsules and draw second $75 million debt tranche with MidCap Financial Trust

2H (targeting 3Q) 2019 - U.S. commercial launch of ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

2H 2019 – Debt funding for ANNOVERA

Summer 2019 - Company to hold Analyst Day

Late 4Q 2019 - BIJUVA 6-month “new to market” payer block expected to end

Full year 2019 - Oral presentations and posters related to clinical benefits of IMVEXXY, BIJUVA and ANNOVERA at medical meetings

Throughout 2019 - Continue to expand BIO-IGNITE with a fuller expansion towards the end of 2019 when the six-month payer block for BIJUVA is expected to end


Summary of Fourth Quarter and Full Year 2018 Financial Results

For the year ended December 31, 2018, net revenues were approximately $16.1 million compared with approximately $16.8 million for the prior year. Net revenues for the fourth quarter of 2018 were approximately $5.1 million compared with net revenues of approximately $4.1 million for the prior year’s quarter. Net revenues from the company’s prescription prenatal vitamin business were approximately $4.2 million for the fourth quarter of 2018, compared with approximately $4.1 million for the fourth quarter of 2017. Net revenues for IMVEXXY for the fourth quarter of 2018 were approximately $0.9 million and were greatly affected by our co-pay assistance program introduced to launch IMVEXXY, which is a maximum $35 out-of-pocket copay assistance program that allows eligible patients to access the product for a reasonable cost regardless of the insurance coverage. The decrease in full-year 2018 net revenues related to lower prenatal vitamins revenues of approximately $1.6 million, primarily due to a lower number of units sold and higher utilization of coupons offered to customers in 2018 as compared to the prior year, partially offset by approximately $1.1 million in net revenues for IMVEXXY. Net revenues for IMVEXXY were greatly affected by our co-pay assistance program. The company expects the net revenues for IMVEXXY to improve as commercial payer coverage for IMVEXXY increases and insurance plans complete the process needed to adjudicate IMVEXXY prescriptions at pharmacies.




Research and development (R&D) expenses for the full-year 2018 decreased to approximately $27.3 million, compared with approximately $33.9 for the prior year. R&D expenses for the fourth quarter of 2018 were approximately $6.8 million compared with approximately $11.0 million for the prior year’s quarter. The decrease in full-year 2018 R&D expenses was primarily as a result of the completion of the REPLENISH Trial for BIJUVA and FDA approval of IMVEXXY and BIJUVA, partially offset by scale-up and manufacturing activities for BIJUVA before FDA approval as well as increased pre-clinical work to support our product pipeline.


Sales, general and administrative (SG&A) expenses for the full-year 2018 increased to approximately $116.0 million, compared with approximately $57.7 million for the prior year. SG&A expenses for the fourth quarter of 2018 were approximately $35.4 million compared with approximately $14.2 million for the prior year’s quarter. The increase in full-year 2018 sales and marketing expenses was primarily a result of increased expenses associated with sales and marketing efforts to support launch and commercialization of IMVEXXY and BIJUVA, including costs related to outsourced sales personnel and their related expenses, physician education and product samples, advertising and travel expenses related to product commercialization. The company expects sales and marketing expenses to continue to increase as it continues the launch of BIJUVA, prepares for the launch of ANNOVERA and continues to support its growing business and commercialization of its products.


Net loss for the full-year 2018 was approximately $132.6 million, or $0.59 per basic and diluted share, compared with approximately $76.9 million, or $0.37 per basic and diluted share, for the full-year of 2017. Net loss for the fourth quarter of 2018 was approximately $39.4 million, or $0.17 per basic and diluted share, compared with approximately $21.4 million, or $0.10 per basic and diluted share, for the fourth quarter of 2017.


Balance Sheet

As of December 31, 2018, the company’s cash on hand totaled approximately $161.6 million, compared with approximately $127.1 million at December 31, 2017. Total outstanding debt, net of issuance costs, was approximately $73.4 million as of December 31, 2018.


Conference Call and Webcast Details

TherapeuticsMD will host a conference call and audio webcast today, at 4:30 p.m. ET to discuss these financial results and provide a business update.


Date: Thursday, February 21, 2019
Time: 4:30 p.m. ET
Telephone Access (US): 866-665-9531
Telephone Access (International): 724-987-6977
Access Code for All Callers: 3494187

A live webcast and audio archive for the event may be accessed on the home page or from the “Investors & Media” section of the TherapeuticsMD website at Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least 30 days. In addition, a digital recording of the conference call will be available for replay beginning two hours after the call's completion and for at least 30 days with the dial-in 855-859-2056 or international 404-537-3406 and Conference ID: 3494187. 


Please see the Full Prescribing Information, including indication and Boxed WARNING, for each TherapeuticsMD product as follows:


About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.


Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXYÒ, ANNOVERATM, BIJUVATM and its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan agreement; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website:

Investor Contact


Nichol Ochsner,

Vice President Investor Relations

561-961-1900, ext. 2088








   December 31,
   2018  2017
Current Assets:      
Cash  $161,613,077   $127,135,628 
Accounts receivable, net of allowance for doubtful accounts of $596,602 and $380,580, respectively   11,063,821    4,328,802 
Inventory   3,267,670    1,485,358 
Other current assets   10,834,693    6,604,284 
Total current assets   186,779,261    139,554,072 
Fixed assets, net   472,683    437,055 
Other Assets:          
License rights   20,000,000    —   
Intangible assets, net   4,092,679    3,099,747 
Other assets   324,855    —   
Security deposit   314,446    139,036 
Total other assets   24,731,980    3,238,783 
Total assets  $211,983,924   $143,229,910 
Current Liabilities:          
Accounts payable  $22,743,841   $4,097,600 
Accrued expenses and other current liabilities   18,334,948    9,223,595 
Total current liabilities   41,078,789    13,321,195 
Long-Term Liabilities:          
Long-term debt   73,381,014    —   
 Total liabilities   114,459,803    13,321,195 
Commitments and Contingencies          
Stockholders' Equity:          
Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding   —      —   
Common stock - par value $0.001; 350,000,000 shares authorized: 240,462,439 and 216,429,642 issued and outstanding, respectively   240,463    216,430 
Additional paid-in capital   616,559,938    516,351,405 
Accumulated deficit   (519,276,280)   (386,659,120)
Total stockholders' equity   97,524,121    129,908,715 
Total liabilities and stockholders' equity  $211,983,924   $143,229,910 







   Three Months Ended December 31,   Year Ended December 31, 
   2018   2017   2018   2017   2016 
Revenues, net  $5,089,523   $4,124,218   $16,099,460   $16,777,713   $19,356,450 
Cost of goods sold   950,750    594,769    2,737,652    2,636,943    4,185,708 
Gross profit   4,138,773    3,529,449    13,361,808    14,140,770    15,170,742 
Operating expenses:                         
Sales, general, and administrative   35,410,875    14,178,958    115,988,954    57,703,370    51,348,414 
Research and development   6,753,190    10,974,956    27,299,138    33,852,993    53,943,477 
Depreciation and amortization   95,341    56,174    293,886    213,117    132,451 
Total operating expenses   42,259,406    25,210,088    143,581,978    91,769,480    105,424,342 
Operating loss    (38,120,633)   (21,680,639)   (130,220,170)   (77,628,710)   (90,253,600)
Other (expense) income                         
Miscellaneous income   823,027    253,309    2,280,844    695,631    367,317 
Interest expense   (2,093,375)   —      (4,677,834)   —      —   
Accreted interest   —      —      —      7,699    10,824 
Total other (expense) income   (1,270,348)   253,309    (2,396,990)   703,330    378,141 
Loss before income taxes    (39,390,981)   (21,427,330)   (132,617,160)   (76,925,380)   (89,875,459)
Provision for income taxes    —      —      —      —      —   
Net loss  $(39,390,981)  $(21,427,330)  $(132,617,160)  $(76,925,380)  $(89,875,459)
Loss per share, basic and diluted:                         
Net loss per share, basic and diluted  $(0.17)  $(0.10)  $(0.59)  $(0.37)  $(0.46)
Weighted average number of common shares outstanding, basic and diluted   238,556,492    216,429,642    225,026,300    205,523,288    196,088,196 









    Year Ended December, 31,  
    2018     2017     2016  
Net loss   $ (132,617,160 )   $ (76,925,380 )   $ (89,875,459 )
Adjustments to reconcile net loss to net cash used in operating activities:                        
Depreciation of fixed assets     181,412       141,601       77,906  
Amortization of intangible assets     112,474       71,516       54,545  
Provision for doubtful accounts     216,022       4,206       2,524,909  
Share-based compensation     8,661,967       6,889,323       17,411,021  
Amortization of deferred financing costs     269,859              
Changes in operating assets and liabilities:                        
Accounts receivable     (6,951,041 )     167,691       (3,975,893 )
Inventory     (1,782,312 )     (409,037 )     (386,168 )
Other current assets     (2,332,335 )     (4,434,130 )     709,907  
Other assets     (324,855 )            
Accounts payable     18,646,241       (3,260,914 )     4,232,340  
Accrued expenses and other current liabilities     9,107,947       1,599,510       84,559  
Net cash used in operating activities     (106,811,781 )     (76,155,614 )     (69,142,333 )
Payment for intellectual property license     (20,000,000 )            
Patent costs     (1,105,407 )     (765,291 )     (845,266 )
Purchase of fixed assets     (217,040 )     (61,817 )     (396,154 )
Payment of security deposit     (175,410 )           (14,036 )
Net cash used in investing activities     (21,497,857 )     (827,108 )     (1,255,456 )
Proceeds from sale of common stock, net of costs     89,907,797       68,572,635       134,863,475  
Proceeds from term loan     75,000,000              
Payment of deferred financing fees     (3,786,918 )            
Proceeds from exercise of options     1,666,208       212,615       989,060  
Proceeds from exercise of warrants           3,798,999       1,373,000  
Net cash provided by financing activities     162,787,087       72,584,249       137,225,535  
Increase (decrease) in cash     34,477,449       (4,398,473 )     66,827,746  
Cash, beginning of period     127,135,628       131,534,101       64,706,355  
Cash, end of period   $ 161,613,077     $ 127,135,628     $ 131,534,101  
Supplemental disclosure of cash flow information                        
Interest paid   $ 1,890,166     $     $  





The following information was filed by Therapeuticsmd, Inc. (TXMD) on Thursday, February 21, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Therapeuticsmd, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Therapeuticsmd, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019) Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019) Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account